# A Study to Evaluate the Effiacy and Safety of HIP0612 in Patients With Gastric Ulcer

> **NCT05656092** · PHASE3 · COMPLETED · sponsor: **Hanmi Pharmaceutical Company Limited** · enrollment: 199 (actual)

## Conditions studied

- Gastric Ulcer

## Interventions

- **DRUG:** HIP0612
- **DRUG:** HPP2202
- **DRUG:** RLD2204
- **DRUG:** HPP2201

## Key facts

- **NCT ID:** NCT05656092
- **Lead sponsor:** Hanmi Pharmaceutical Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-03-06
- **Primary completion:** 2024-12-19
- **Final completion:** 2024-12-19
- **Target enrollment:** 199 (ACTUAL)
- **Last updated:** 2025-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05656092

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05656092, "A Study to Evaluate the Effiacy and Safety of HIP0612 in Patients With Gastric Ulcer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05656092. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*